Arbutus Biopharma Corp. buy Maxi_Scalibusa
Start price
16.11.20
/
50%
€3.45
Target price
16.11.21
-
Performance (%)
-14.81%
End price
17.11.21
€2.94
Summary
This prediction ended on 17.11.21 with a price of €2.94. The prediction for Arbutus Biopharma Corp. disappointed with a performance of -14.81%. Maxi_Scalibusa has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Arbutus Biopharma Corp. | -6.349% | -6.349% | 21.985% | 56.291% |
| iShares Core DAX® | -0,37 % | 8,40 % | 6,76 % | 47,91 % |
| iShares Nasdaq 100 | 2,27 % | 15,23 % | 36,18 % | 94,08 % |
| iShares Nikkei 225® | 1,43 % | 14,42 % | 43,11 % | 64,80 % |
| iShares S&P 500 | 1,22 % | 10,49 % | 27,28 % | 66,76 % |
According to Maxi_Scalibusa what are the pros and cons of Arbutus Biopharma Corp. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
Cons
Comments by Maxi_Scalibusa for this prediction
In the thread Arbutus Biopharma Corp. diskutieren
Buy Arbutus Biopharma Corp.
In the thread Trading Arbutus Biopharma Corp.
Die von Maxi_Scalibusa gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Maxi_Scalibusa for Arbutus Biopharma Corp.
Arbutus Biopharma Corp.
Start price
Target price
Perf. (%)
€4.85
01.12.21
01.12.21
-
01.12.22
01.12.22
-53.67%
02.12.22
02.12.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Stable Large shareholder and/or long term investor
Future proof or reliable business model
